Barclays’s Sensus Healthcare SRTS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.3K Buy
3,440
+654
+23% +$2.02K ﹤0.01% 4831
2026
Q2
$8.41K Buy
2,786
+48
+2% +$168 ﹤0.01% 4716
2026
Q1
$10.9K Hold
2,738
– – ﹤0.01% 4688
2025
Q4
$10.9K Hold
2,738
– – ﹤0.01% 4927
2025
Q3
$8.6K Hold
2,738
– – ﹤0.01% 5033
2025
Q2
$13K Buy
2,738
+869
+46% +$4.07K ﹤0.01% 4896
2025
Q1
$8.84K Sell
1,869
-3,197
-63% -$18.6K ﹤0.01% 4879
2024
Q4
$35.1K Buy
+5,066
New +$37.1K ﹤0.01% 4829
2023
Q2
– Sell
-2,379
Closed -$12.4K – 5052
2023
Q1
$12.4K Sell
2,379
-3,940
-62% -$28.3K ﹤0.01% 4723
2022
Q4
$46.9K Buy
6,319
+5,547
+719% +$50K ﹤0.01% 4574
2022
Q3
$10K Buy
+772
New +$9.22K ﹤0.01% 4314
2018
Q4
– Sell
-11
Closed – – 7304
2018
Q3
$0 Buy
+11
New +$80 ﹤0.01% 7373

Other funds holding SRTS

Barclays's SRTS Position: Q3 2026 in Review

Barclays increased its Sensus Healthcare (SRTS) stake by 23% in Q3 2026, buying an estimated $2.02K and bringing the position to 3,440 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4831.

Barclays first reported a position in SRTS in Q3 2018 and has held it in 12 quarters since. The position peaked at $46.9K in Q4 2022. 37 funds tracked by Wall St. Rank hold SRTS as of Q3 2026.

  • Barclays held 3,440 shares of Sensus Healthcare worth $10.3K as of Q3 2026.
  • Barclays bought 654 Sensus Healthcare shares in Q3 2026, an estimated $2.02K.
  • Sensus Healthcare made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4831 holding.
  • Barclays first reported a position in Sensus Healthcare in Q3 2018 and has held it in 12 quarters since.
  • Barclays's Sensus Healthcare position peaked at $46.9K in Q4 2022.
  • 37 funds tracked by Wall St. Rank held Sensus Healthcare as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.